On April 27, 2022 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported, in conjunction with its Asia Pacific partner BeiGene, the acceptance of two abstracts for poster presentations at the upcoming 2022 ASCO (Free ASCO Whitepaper) Annual Meeting taking place virtually and in Chicago, IL from June 3 – 7, 2022 (Press release, Zymeworks, APR 27, 2022, View Source [SID1234613042]). The presentations will provide new clinical data from two early-stage studies of zanidatamab in first-line oncology settings.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first poster, scheduled for presentation on Saturday, June 4, highlights Phase 1b/2 data of zanidatamab in combination with the CAPOX regimen of chemotherapy and the PD-1 inhibitor tislelizumab, for first-line treatment of HER2-positive advanced/metastatic gastric and gastroesophageal junction adenocarcinoma (GEA). This is the first clinical data presentation of zanidatamab in combination with chemotherapy and a PD-1 inhibitor. The regimen evaluated in this study is also being used in one of the treatment arms of the ongoing Phase 3 HERIZON-GEA-01 study (NCT05152147).
The second poster, scheduled for presentation on Monday, June 6, includes preliminary Phase 1b/2 data of zanidatamab in combination with docetaxel, for first-line treatment of advanced/metastatic HER2-positive breast cancer. This will be the first clinical data presentation of zanidatamab in a first-line setting of advanced/metastatic HER2-positive breast cancer.
The poster presentations will be available on their respective presentation dates on the conference website as well as the Zymeworks website.
Presentation Details
Title: Zanidatamab, a HER2-targeted bispecific antibody, in combination with chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GJEC): Preliminary results from a Phase 1b/2 study
Abstract: 4032
Session Title: Gastrointestinal Cancer – Gastroesophageal, Pancreatic and Hepatobiliary
Date: Saturday June 4, 2022
Time: 08:00 –11:00 am CDT
Title: Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study
Abstract: 1031
Session Title: Breast Cancer – Metastatic
Date: Monday June 6, 2022
Time: 08:00 –11:00 am CDT
Zymeworks plans to host a webcast to discuss the clinical results presented at ASCO (Free ASCO Whitepaper) as well as an update on the Company’s clinical development strategy for zanidatamab. Call details and presentation materials will be available on the Zymeworks website at View Source